Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1

详细信息    查看全文

• 作者：Steven P. Marso ; MD^a ; ^{smarso@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Darren K. McGuire ; MD ; MHSc^a ; Bernard Zinman ; MD ; FRCPC ; FACP^b ; Neil R. Poulter ; FMedSci^c ; Scott S. Emerson ; MD ; PhD^d ; Thomas R. Pieber ; MD^e ; Richard E. Pratley ; MD^f ; Poul-Martin Haahr ; MD^g ; Martin Lange ; MD ; PhD^g ; Kirstine Brown Frandsen ; MD^g ; Rasmus Rabø ; l ; MD ; PhD^g ; John B. Buse ; MD ; PhD^h
• 刊名：American Heart Journal
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：179
• 期：Complete
• 页码：175-183
• 全文大小：209 K

文摘

DEVOTE was designed to evaluate the cardiovascular safety of insulin degludec (IDeg) vs insulin glargine U100 (IGlar) in patients with T2D at high risk of cardiovascular events. DEVOTE is a phase 3b, multicenter, international, randomized, double-blind, active comparator-controlled trial, designed as an event-driven trial that would continue until 633 positively adjudicated primary events were accrued. The primary end point was the time from randomization to a composite outcome consisting of the first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Patients with T2D at high risk of cardiovascular complications were randomized 1:1 to receive either IDeg or IGlar, each added to background therapies. This trial was designed to demonstrate statistical noninferiority of IDeg vs IGlar for the primary end point. DEVOTE enrolled 7,637 patients between October 2013 and November 2014 at 436 sites in 20 countries. Of these, 6,506 patients had prior cardiovascular disease or chronic kidney disease, and the remainder had multiple cardiovascular risk factors. DEVOTE was designed to provide conclusive evidence regarding the cardiovascular safety of IDeg relative to IGlar in a high-risk population of patients with T2D.